JG
RNAM

Jefferies Group’s Avidity Biosciences RNAM Stock Holding History

Jefferies Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$163K Buy
+10,000
New +$191K ﹤0.01% 1395

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Jefferies Group's RNAM Position: Q3 2022 in Review

Jefferies Group opened a new position in Avidity Biosciences (RNAM) in Q3 2022: 10,000 shares worth $163K. The stake represents ﹤0.01% of the portfolio and ranks #1395 among its holdings.

127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

  • Jefferies Group held 10,000 shares of Avidity Biosciences worth $163K as of Q3 2022.
  • Avidity Biosciences was a new Jefferies Group position in Q3 2022.
  • Avidity Biosciences made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1395 holding.
  • 127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.